Oral pill for moderate-to-severe plaque psoriasis
Part of Skin clinical trials.
This trial tests an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. It aims to see how safe and effective it is compared to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had plaque psoriasis for at least 12 months, with 10% or more of your body affected.
- Your psoriasis is moderate to severe, making you a candidate for systemic treatment or light therapy.
- You have not used certain psoriasis pills, injections, or topical treatments in the past few weeks to 3 months.
- You do not have certain heart conditions or abnormal lab results (like liver or kidney issues).
- You have not had significant mental health issues, including suicidal thoughts or attempts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.